S1. The expression of CD137 on splenic CD8+ T cells and the expression of PD1 and CD137 on CD8+ TILs of tumor bearing mice. S2. Analysis of TILs. (A) CD137 expression of TILs and RLN cells. S3. Transfection of TCR cDNA into splenic T cells. S4. IFN-γ-induced expression of MHC class I molecules on the surface of B16F10 cells. S5. The IFN-γ-secretion of TIL-derived TCR-transduced spleen T cells. S6. The cytotoxicity of TIL-derived TCR-expressing T cells against unstimulated B16F10 cells. S7. A correlation between the INF-γ production and the cytotoxicity. S8. Transfection efficiency of TCR gene into splenic T cellsforin vivoexperiment. S9. MHC-restriction of TIL-derived TCR. (A) Expression of H-2Kband H-2Dbmolecules on H-2Kbor H-2DbcDNA-transfected B16F10 cells. S10. IFN-γ-induced expression of MHC class I molecules on the surface of cells. Supplementary Table 1. Clonally expanded populations in human cancer TILs
ARTICLE ABSTRACT
T-cell receptor (TCR) gene therapy is a promising next-generation antitumor treatment. We previously developed a single–T-cell analysis protocol that allows the rapid capture of paired TCRα and β cDNAs. Here, we applied the protocol to analyze the TCR repertoire of tumor-infiltrating lymphocytes (TIL) of various cancer patients. We found clonally expanded populations of T cells that expressed the same clonotypic TCR in 50% to 70% of CD137+CD8+ TILs, indicating that they responded to certain antigens in the tumor environment. To assess the tumor reactivity of the TCRs derived from those clonally expanded TILs in detail, we then analyzed the CD137+CD8+ TILs from the tumor of B16F10 melanoma cells in six C57BL/6 mice and analyzed their TCR repertoire. We also found clonally expanded T cells in 60% to 90% of CD137+CD8+ TILs. When the tumor reactivity of dominant clonotypic TCRs in each mouse was analyzed, 9 of 13 TCRs induced the secretion of IFNγ in response to, and showed killing of, B16F10 cells in vitro, and 2 of them showed strong antitumor activity in vivo. Concerning their antigen specificity, 7 of them reacted to p15E peptide of endogenous murine leukemia virus-derived envelope glycoprotein 70, and the rest reacted to tumor-associated antigens expressed on EL4 lymphoma as well as B16 melanoma cells. These results show that our strategy enables us to simply and rapidly obtain the tumor-specific TCR repertoire with high fidelity in an antigen- and MHC haplotype–independent manner from primary TILs. Cancer Immunol Res; 6(4); 378–88. ©2018 AACR.
